Biogen Inc.

LSE:0R1B Stock Report

Market Cap: US$23.0b

Biogen Valuation

Is 0R1B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R1B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0R1B ($158.97) is trading below our estimate of fair value ($734.68)

Significantly Below Fair Value: 0R1B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R1B?

Key metric: As 0R1B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0R1B. This is calculated by dividing 0R1B's market cap by their current earnings.
What is 0R1B's PE Ratio?
PE Ratio14.2x
EarningsUS$1.62b
Market CapUS$23.01b

Price to Earnings Ratio vs Peers

How does 0R1B's PE Ratio compare to its peers?

The above table shows the PE ratio for 0R1B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average52x
GNS Genus
142.9x37.7%UK£1.1b
BVXP Bioventix
24.2xn/aUK£195.7m
GSK GSK
21.8x21.9%UK£54.8b
HIK Hikma Pharmaceuticals
19x12.8%UK£4.3b
0R1B Biogen
14.2x12.4%US$23.0b

Price-To-Earnings vs Peers: 0R1B is good value based on its Price-To-Earnings Ratio (14.2x) compared to the peer average (52x).

Price to Earnings Ratio vs Industry

How does 0R1B's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0R1B 14.2xIndustry Avg. 27.0xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0R1B is good value based on its Price-To-Earnings Ratio (14.2x) compared to the European Biotechs industry average (27x).

Price to Earnings Ratio vs Fair Ratio

What is 0R1B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R1B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.2x
Fair PE Ratio28.8x

Price-To-Earnings vs Fair Ratio: 0R1B is good value based on its Price-To-Earnings Ratio (14.2x) compared to the estimated Fair Price-To-Earnings Ratio (28.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0R1B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$158.97
US$251.70
+58.3%
18.8%US$342.00US$180.00n/a29
Nov ’25US$173.99
US$255.70
+47.0%
17.1%US$342.00US$180.00n/a29
Oct ’25US$190.45
US$270.19
+41.9%
13.7%US$342.00US$190.00n/a30
Sep ’25US$203.57
US$271.42
+33.3%
13.0%US$342.00US$190.00n/a30
Aug ’25US$207.27
US$278.42
+34.3%
13.6%US$350.00US$200.00n/a30
Jul ’25US$232.20
US$283.15
+21.9%
14.4%US$350.00US$200.00n/a30
Jun ’25US$224.47
US$284.78
+26.9%
14.2%US$350.00US$200.00n/a29
May ’25US$215.49
US$286.18
+32.8%
13.4%US$350.00US$200.00n/a31
Apr ’25US$215.50
US$300.47
+39.4%
12.7%US$400.00US$230.00n/a30
Mar ’25US$221.70
US$300.47
+35.5%
12.7%US$400.00US$230.00n/a30
Feb ’25US$247.80
US$313.00
+26.3%
11.1%US$406.00US$245.00n/a30
Jan ’25US$258.40
US$312.61
+21.0%
10.2%US$394.00US$239.00n/a31
Dec ’24US$233.34
US$318.34
+36.4%
11.1%US$394.00US$239.00n/a29
Nov ’24US$238.50
US$324.34
+36.0%
9.2%US$400.00US$266.00US$173.9929
Oct ’24US$258.04
US$327.51
+26.9%
10.5%US$436.00US$269.00US$190.4529
Sep ’24US$267.60
US$325.96
+21.8%
10.2%US$436.00US$269.00US$203.5728
Aug ’24US$268.75
US$335.21
+24.7%
9.7%US$436.00US$276.00US$207.2728
Jul ’24US$283.56
US$336.33
+18.6%
8.5%US$398.00US$263.00US$232.2027
Jun ’24US$304.06
US$334.26
+9.9%
8.4%US$398.00US$263.00US$224.4727
May ’24US$289.77
US$329.48
+13.7%
8.8%US$398.00US$263.00US$215.4927
Apr ’24US$274.01
US$322.50
+17.7%
9.7%US$388.00US$249.00US$215.5026
Mar ’24US$273.49
US$322.19
+17.8%
9.6%US$388.00US$249.00US$221.7026
Feb ’24US$287.15
US$323.69
+12.7%
10.1%US$402.00US$249.00US$247.8026
Jan ’24US$273.09
US$320.35
+17.3%
8.9%US$370.00US$247.00US$258.4026
Dec ’23US$301.20
US$319.38
+6.0%
9.3%US$370.00US$247.00US$233.3426
Nov ’23US$281.14
US$304.88
+8.4%
12.0%US$370.00US$218.00US$238.5026

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%